Best Peptides for Sleep and Recovery: Evidence Ranked

By the Peptide Bureau editorial desk Sleep & Recovery 11 min read Updated 1 November 2026

Short answer: the best peptide for sleep on the evidence is DSIP, and even DSIP is weak: two small placebo-controlled trials in chronic insomnia, one positive (14 people, 7 nights) and one that found only weak effects (16 people, 5 nights). The growth hormone-axis peptides (CJC-1295, ipamorelin, tesamorelin) rest on studies of intravenous GHRH and ghrelin in healthy men, not on trials of the peptides themselves. Epitalon, Selank, Cerebrolysin and BPC-157 have no human sleep trial we could find, and we found no approved sleep indication for any of the seven. Research use only, not medical advice.

Updated 1 November 2026

Best Peptides for Sleep and Recovery: Evidence Level for Each

Ranked by the strength of the human evidence on sleep itself. The regulatory column describes FDA's compounding and approval pages, not whether a compound is safe or effective for sleep.

Rank and peptide	Human sleep evidence	Study size	Animal or mechanistic only?	FDA status
1. DSIP	Two placebo-controlled trials in chronic insomnia with conflicting conclusions (1987 positive, 1992 weak)	14 and 16 people	No, small human trials exist	Listed as emideltide (DSIP) in FDA's table of nominated-but-withdrawn bulk substances
2. CJC-1295 + ipamorelin	No sleep trial of either. Indirect: intravenous GHRH and ghrelin raised slow-wave sleep in men	Ghrelin study: 7 men. GHRH study: healthy young men	Yes for the peptides themselves; ipamorelin data are from rat cells, rats and swine	CJC-1295 in the withdrawn table; ipamorelin acetate in category 2 (503B interim policy, added 29 September 2023)
3. Epitalon	No sleep trial. Melatonin output rose with a related pineal peptide complex	55 elderly people (related complex, melatonin metabolite only)	Yes, plus a melatonin-output study of a related preparation	In the withdrawn table
4. Selank	No sleep trial. Human data are on anxiety	40 people on Selank plus phenazepam in the anxiety study	No human sleep data; anxiety trials only	Selank acetate (TP-7) in the withdrawn table
5. Tesamorelin	No published sleep result found. A 2006 review lists sleep disorders among Phase II programs	None found	No sleep data found	FDA-approved as EGRIFTA (first approval 10 November 2010) for excess abdominal fat in HIV-infected adults with lipodystrophy, not sleep
6. Cerebrolysin	None. Rat studies of memory after sleep deprivation	None in people	Yes, animal only	Not on the FDA bulk-substances page
7. BPC-157	None	None	Yes	In the withdrawn table

FDA status comes from FDA's page on bulk drug substances that may present significant safety risks (content current as of 22 April 2026) and, for tesamorelin, Drugs@FDA and DailyMed. Appearing in the nominated-but-withdrawn table is not an approval, and it is not a safety verdict either. Sources are listed at the end of the page.

Sleep matters to recovery, but it is also where research peptides are most prone to placebo effects, because the outcome is subjective. This page ranks the seven compounds people most often ask about by the strength of the human evidence on sleep itself. Where we describe doses, they are community-reported protocols, not trial doses and not recommendations.

Why Slow-Wave Sleep Comes Up in Every Peptide Sleep Claim

Best vendor for DSIP right now: Amino Club

5mg vial, $29.99 per vial ($6.00 per mg), list price checked 2026-09-08. The vendor Bureau readers order from most this year, lowest price per mg on most of what we track, batch COA on every product page. Partner code 100 at checkout takes 20% off a first order there, and keeps the order counted for the Bureau. Research use only.

Check price at Amino Club Compare all vendors

Most of the claims below are about slow-wave (deep) sleep, because growth hormone release is linked to it. A 1988 study in Psychoneuroendocrinology found that on baseline nights GH bursts coincided with slow-wave sleep, but that depriving people of slow-wave sleep did not significantly change GH peak amplitude, and concluded that the timing of nocturnal GH and cortisol secretion depends more on sleep onset than on slow-wave sleep. In plain terms: the link between GH and deep sleep is real but looser than the marketing suggests, so a GH-releasing peptide cannot be assumed to deepen sleep.

Calculate your draw for any compound on this page

Pick the peptide, enter your vial, water and dose, and get the exact syringe mark plus doses per vial. Twenty-seven compounds, free, no signup.

Open the peptide calculator peptulator.com, the Bureau's independent tool

1DSIP (Delta Sleep-Inducing Peptide)

DSIP was described in the 1970s as a nonapeptide from rabbit work (Monnier et al., Experientia, 1977). It is the only peptide here with placebo-controlled human sleep trials, and they disagree. In a 1987 trial, 14 middle-aged people with chronic insomnia received DSIP for seven consecutive nights against placebo, and the author concluded it improved night sleep and daytime functioning. In a 1992 double-blind trial, 16 chronic insomniacs received intravenous DSIP (25 nmol/kg) or glucose placebo for five consecutive laboratory nights; the authors judged the effects weak and concluded that short-term DSIP treatment is not likely to be of major therapeutic benefit. Our DSIP guide covers the compound in full.

Evidence level: low. Two small human trials, conflicting conclusions, no larger replication that we could find.

Community-reported protocol (not trial dosing): 100 to 200mcg subcutaneous, 30 to 60 minutes before bed. The trials used a different route and schedule.

2CJC-1295 + Ipamorelin Stack

The case for this stack is indirect. In a 1993 study, single intravenous doses of GHRH increased slow-wave sleep in healthy young men, particularly when given at a time of decreased sleep propensity (Kerkhofs et al., American Journal of Physiology). Intravenous ghrelin, which acts through a related receptor family to ipamorelin, increased slow-wave sleep in seven men in a 2003 study (Weikel et al.). Ipamorelin itself was characterised in 1998, in rat cells, rats and swine, as stimulating GH release through a GHRP-like receptor (Raun et al., European Journal of Endocrinology). None of that is a sleep trial of CJC-1295 or ipamorelin, and a PubMed search for ipamorelin, CJC-1295 or tesamorelin together with sleep returned no sleep trial of any of them. See the CJC-1295 + ipamorelin stack guide and ipamorelin dosage for the protocol side, and ipamorelin and CJC-1295 side effects for what the trials reported on tolerability.

Evidence level: indirect only. Human data are on intravenous GHRH and ghrelin, not on these peptides. Reports of better sleep are anecdotal.

Community-reported protocol: 100mcg of each, subcutaneous, before bed, 5 nights per week, in 12-week cycles.

Next step: if you are working with this pair, our best place to buy CJC-1295 and ipamorelin page compares vendors, and the CJC-1295 + ipamorelin dosage calculator turns vial size, water and dose into syringe units.

3Epitalon

Epitalon (Ala-Glu-Asp-Gly) is a pineal-derived tetrapeptide. A 2025 review in the International Journal of Molecular Sciences describes a direct influence on melatonin synthesis, with the melatonin figures coming from monkeys, and says it remains uncertain whether this is the only mechanism. A 2017 Russian-language study of a related pineal peptide complex, Pineamin, in 55 elderly people with reduced pineal melatonin function reported a 1.9-fold rise in night-time urinary melatonin metabolite. That measured melatonin output, not sleep, and it was not epitalon itself. We found no human trial of epitalon with a sleep outcome.

Evidence level: very low for sleep. Animal and mechanistic data, plus a melatonin-output study of a related preparation.

Community-reported protocol: 5 to 10mg subcutaneous daily for 10 to 20 days, repeated a few times a year.

4Selank

Selank is an anxiolytic peptide, and the human literature we found concerns anxiety disorders (for example a 2015 Russian paper on optimising anxiety treatment with Selank, Medvedev et al.), not sleep. A 2021 pharmacology review in the Journal of Clinical Pharmacology calls Selank a poorly studied Russian drug with GABAergic mechanisms that is sold to US consumers as a dietary supplement. If it helps sleep at all, the route is plausibly through anxiety, and that is an inference, not a finding. See the Selank guide.

Evidence level: none for sleep. Some human data for anxiety.

Community-reported protocol: 250 to 500mcg intranasal, with the last dose about 30 minutes before bed when sleep is the target.

5Tesamorelin

Tesamorelin is a synthetic growth hormone-releasing factor developed for HIV-associated lipodystrophy (it was in Phase III when reviewed in Current Opinion in Investigational Drugs in 2006). It is a GHRH analog, so it sits in the same indirect argument as CJC-1295: GHRH raised slow-wave sleep in healthy young men when given intravenously. The 2006 review of tesamorelin lists sleep disorders among its Phase II programs, but we found no published sleep trial of it. Tesamorelin is FDA-approved as EGRIFTA for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, not for sleep. See tesamorelin for what it is actually studied for.

Evidence level: none published for sleep that we found. Indirect argument from GHRH only.

Community-reported protocol: 1 to 2mg subcutaneous before bed in 12-week cycles.

6Cerebrolysin

Cerebrolysin is a porcine brain-derived peptide mixture, not a single peptide. The sleep-related papers we found are rat studies of sleep deprivation, for example a 2020 Physiology and Behavior paper on Cerebrolysin and sleep-deprivation-induced memory impairment and oxidative stress. That is protection against the effects of lost sleep in rats, not evidence that it improves sleep in people. An earlier version of this page said it normalises sleep in people with brain injury or dementia; we could not source that and removed it.

Evidence level: animal data only, and not on sleep quality itself.

7BPC-157

BPC-157 is on this list only because people report better sleep when chronic pain or gut symptoms settle. There is no sleep data for it. The published BPC-157 literature we found is dominated by animal studies and narrative reviews, with few human studies. Any sleep effect would be indirect, and it is unproven. See the BPC-157 guide, and recovery peptides for what the evidence on repair supports.

Evidence level: none for sleep.

Community-reported protocol: 250 to 500mcg daily for 4 to 8 weeks per cycle.

Combining These: What Is Reported and What Is Tested

Community protocols often pair one "direct" sleep peptide (DSIP or Selank) with a GH-axis peptide (CJC-1295 + ipamorelin). No trial has tested any combination for sleep, so treat this as reported practice, not a result.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the six vendors we score.

Build your stack, 2 minutes

Do not combine research peptides with prescription sleep medication, or use them if you are pregnant or have a medical condition, without a clinician. The evidence above is too thin to tell you how they interact.

Get the Dispatch

One research note, one vendor deal, once a week. Free dosing guide on confirm.

Double opt-in. Unsubscribe with one click. Research use only.

Peptides for Sleep and Recovery: Which Question Are You Asking?

Sleep and recovery are separate questions with separate evidence. For sleep itself, DSIP is the only peptide here with placebo-controlled human sleep trials, and those trials disagree. For recovery, BPC-157 is the compound people usually mean, and we found no sleep data for it; the repair evidence is covered on the recovery peptides page. The idea that a growth hormone-releasing peptide improves sleep and recovery together rests on a link between GH and deep sleep that a 1988 study of ten healthy men found to be looser than marketing implies.

What These Peptides Will Not Fix

Untreated sleep apnea will not respond to peptides. Get a sleep study before assuming your problem is biochemical.

The best-evidenced treatment for chronic insomnia is not a drug. The American College of Physicians 2016 guideline recommends that all adults with chronic insomnia receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment, and rates that evidence as moderate quality. No peptide on this page has evidence of that standard.

Severe insomnia driven by trauma, depression, or chronic anxiety needs proper treatment first. Nothing here replaces it.

Where to Source These Peptides

Because the outcome is subjective, a poor batch and a placebo are hard to tell apart, so check the batch COA before judging any result. A COA does not make a compound effective; it only tells you what is in the vial.

For DSIP, Epitalon, Selank, and the GH-axis peptides, the vendors we score highest on batch COAs are Apollo Peptide Sciences, Pantheon Peptides, and Amino Club. For Cerebrolysin specifically, check Limitless Life Peptides, which carries the harder-to-find specialty compounds.

How Long Do Trials Run, and What Should You Expect?

The two DSIP trials ran for seven nights and five nights, which is the entire controlled timeline for any peptide on this page. There is no trial-based timeline for the others. Reports from users vary and are not evidence. If you see no change after a couple of weeks on a properly stored, correctly reconstituted product, the more likely explanations are the environment, caffeine timing, an undiagnosed condition such as sleep apnea, or no effect from the peptide.

Peptides for Better Sleep: Frequently Asked Questions

What is the best peptide for sleep?

No peptide has an approved sleep indication, so there is no proven best. DSIP is the most studied, with two small placebo-controlled trials in chronic insomnia: one of 14 people reported better sleep and daytime function, and one of 16 people found only weak effects and concluded the benefit was unlikely to be major. The other peptides on this list have no human sleep trial we could find.

Does DSIP help you sleep?

The evidence is mixed and small. A 1987 trial gave DSIP for seven consecutive nights to 14 middle-aged people with chronic insomnia and the author reported improved night sleep and daytime functioning. A 1992 double-blind trial of 16 chronic insomniacs gave intravenous DSIP or glucose placebo for five nights and found statistically weak effects, concluding that short-term DSIP treatment is not likely to be of major therapeutic benefit.

Do CJC-1295 and ipamorelin improve sleep?

Not shown in trials. Intravenous growth hormone-releasing hormone (GHRH) increased slow-wave sleep in healthy young men in a 1993 study, which is the basis for the idea, but a PubMed search for ipamorelin, CJC-1295 or tesamorelin together with sleep returned no sleep trial of these compounds. Reports of better sleep on these peptides are anecdotal.

Does epitalon help with sleep?

We found no human sleep trial of epitalon. Reviews describe an influence on melatonin synthesis, with melatonin data from monkeys, and a Russian-language study of a related pineal peptide complex reported higher night-time urinary melatonin metabolite in 55 elderly people. That measured melatonin output, not sleep.

Is Selank a sleep peptide or an anxiety peptide?

The human literature we found on Selank concerns anxiety, not sleep. A 2021 pharmacology review calls Selank a poorly studied Russian drug with GABAergic mechanisms that is sold to US consumers as a dietary supplement. Any sleep benefit would be indirect and is not established.

What has better evidence than peptides for insomnia?

Cognitive behavioral therapy for insomnia (CBT-I). The American College of Physicians 2016 guideline recommends that all adults with chronic insomnia receive CBT-I as the initial treatment, and rates the supporting evidence as moderate quality.

What is the best peptide for sleep and recovery?

For sleep, DSIP is the only peptide with placebo-controlled human sleep trials, and they conflict: a 1987 trial of 14 people reported better sleep, while a 1992 trial of 16 people found only weak effects. For recovery, BPC-157 is the name people usually raise, but we found no sleep data for it. No peptide has proven benefit for both.

Is any peptide FDA-approved for sleep?

We found no approved sleep indication for any peptide on this page. Tesamorelin has an FDA-approved product, EGRIFTA, indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. FDA lists DSIP (emideltide), epitalon, Selank acetate, CJC-1295 and BPC-157 only in a table of nominated-but-withdrawn bulk drug substances, and ipamorelin acetate in category 2 under its 503B interim policy, on a page current as of 22 April 2026.

Key Takeaways

DSIP is the best-studied sleep peptide, with two small human trials that disagree
CJC-1295, ipamorelin and tesamorelin have no published sleep trials that we found; the case rests on intravenous GHRH and ghrelin studies in healthy young men
Epitalon, Selank, Cerebrolysin and BPC-157 have no human sleep trial that we could find
The link between growth hormone release and deep sleep is looser than marketing suggests
CBT-I, not a peptide, is the guideline-recommended first treatment for chronic insomnia
Doses on this page are community-reported protocols, not recommendations

Sources (checked 1 November 2026)

Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol 1987. PubMed 3622582 Checked 1 November 2026.
Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology 1992. PubMed 1299794 Checked 1 November 2026.
Monnier M et al. The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia 1977. PubMed 862769 Checked 1 November 2026.
Kerkhofs M et al. Sleep-promoting effects of growth hormone-releasing hormone in normal men. Am J Physiol 1993. PubMed 8476038 Checked 1 November 2026.
Weikel JC et al. Ghrelin promotes slow-wave sleep in humans. Am J Physiol Endocrinol Metab 2003. PubMed 12388174 Checked 1 November 2026.
Born J et al. The significance of sleep onset and slow wave sleep for nocturnal release of growth hormone (GH) and cortisol. Psychoneuroendocrinology 1988. PubMed 3406323 Checked 1 November 2026.
Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PubMed 9849822 Checked 1 November 2026.
Araj SK et al. Overview of Epitalon, highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci 2025. PubMed 40141333 Checked 1 November 2026.
Trofimova SV et al. Pineamin increased pineal melatonin synthesis in elderly people. Adv Gerontol 2017. PubMed 28849889 Checked 1 November 2026.
Doyno CR et al. Sedative-hypnotic agents that impact gamma-aminobutyric acid receptors: focus on flunitrazepam, gamma-hydroxybutyric acid, phenibut, and selank. J Clin Pharmacol 2021. PubMed 34396551 Checked 1 November 2026.
Medvedev VE et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova 2015. PubMed 26356395 Checked 1 November 2026.
Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs 2006. PubMed 17086939 Checked 1 November 2026.
Alzoubi KH et al. Cerebrolysin prevents sleep deprivation induced memory impairment and oxidative stress. Physiol Behav 2020. PubMed 31987894 Checked 1 November 2026.
Qaseem A et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016. PubMed 27136449 Checked 1 November 2026.
Theratechnologies. EGRIFTA SV (tesamorelin) label, Indications and Usage. DailyMed. Checked 1 November 2026.
FDA, Drugs@FDA, EGRIFTA (tesamorelin acetate), BLA 022505, original approval 10 November 2010. accessdata.fda.gov. Checked 1 November 2026.
FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). fda.gov. Checked 1 November 2026.

Where the Bureau sources this

The vendors we rank highest for sleep peptides on the 2026 scorecard. Amino Club is the one Bureau readers order from most; code 100 takes 20% off a first order there. Research use only.

Amino Club PSPeptides Limitless Life Peptides

The Peptide Bureau editorial desk. Peptide Bureau is a small independent research team covering peptide dosing, safety and vendors. We are not clinicians; nothing here is medical advice. How the Bureau works.